Body Mass Index, HbA1c, and Serum C-Reactive Protein Are Predictors of Secondary Failure in Infliximab Continuance for Psoriasis Patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Body Mass Index, HbA1c and Serum C-Reactive Protein Are Predictors of Secondary Failure in Infliximab Continuance for Japanese Psoriasis Patients: A Hospital-Based Retrospective Case-Control Study
J Dermatol 2021 Aug 06;[EPub Ahead of Print], H Terui, M Asano, R Shimada-Omori, K Tsuchiyama, T Takahashi, M Nasu-Tamabuchi, A Hagiwara-Takita, Y Kusakari, T Ohtani, S Aiba, K YamasakiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.